muLIF Can Facilitate Ex Vivo Expansion of Human Fetal BM CD34+ thy-1+ Cells
| Treatments . | Frequency of CD34+thy-1+/ Positive Wells . | Percentage of CD34+ thy-1+ Cells . |
|---|---|---|
| IL-3 + IL-6 + GM-CSF + SCF | 0.3% (1/300) | 1.2 |
| IL-3 + IL-6 + GM-CSF + SCF + muLIF | 10% (30/300) | 15 ± 2 |
| IL-3 + IL-6 + GM-CSF + SCF + huLIF | 12% (35/300) | 15 ± 1 |
| Treatments . | Frequency of CD34+thy-1+/ Positive Wells . | Percentage of CD34+ thy-1+ Cells . |
|---|---|---|
| IL-3 + IL-6 + GM-CSF + SCF | 0.3% (1/300) | 1.2 |
| IL-3 + IL-6 + GM-CSF + SCF + muLIF | 10% (30/300) | 15 ± 2 |
| IL-3 + IL-6 + GM-CSF + SCF + huLIF | 12% (35/300) | 15 ± 1 |
Cells from individual wells were analyzed by flow cytometry after 5 weeks in culture. See Table 3 for legend.